Login / Signup

Nemacol is a small molecule inhibitor of C. elegans vesicular acetylcholine transporter with anthelmintic potential.

Sean HarringtonJacob PycheAndrew R BurnsTina SpalholzKaetlyn T RyanRachel J BakerJustin ChingLucien RufenerMark LautensDaniel KulkeAlexandre VernudachiMostafa ZamanianWinnie Deuther-ConradPeter BrustPeter J Roy
Published in: Nature communications (2023)
Nematode parasites of humans and livestock pose a significant burden to human health, economic development, and food security. Anthelmintic drug resistance is widespread among parasites of livestock and many nematode parasites of humans lack effective treatments. Here, we present a nitrophenyl-piperazine scaffold that induces motor defects rapidly in the model nematode Caenorhabditis elegans. We call this scaffold Nemacol and show that it inhibits the vesicular acetylcholine transporter (VAChT), a target recognized by commercial animal and crop health groups as a viable anthelmintic target. We demonstrate that it is possible to create Nemacol analogs that maintain potent in vivo activity whilst lowering their affinity to the mammalian VAChT 10-fold. We also show that Nemacol enhances the ability of the anthelmintic Ivermectin to paralyze C. elegans and the ruminant nematode parasite Haemonchus contortus. Hence, Nemacol represents a promising new anthelmintic scaffold that acts through a validated anthelmintic target.
Keyphrases
  • human health
  • risk assessment
  • small molecule
  • plasmodium falciparum
  • climate change
  • healthcare
  • public health
  • anti inflammatory
  • protein protein
  • social media
  • life cycle
  • toxoplasma gondii